‘Pharma Bro’, who drove up anti-HIV drug costs by defrauding investors, gets imprison

The “Pharma Bro” was convicted last year to defraud financial specialists by demonstrating counterfeit record explanations of two failing hedge funds that he ran.

The main drug prices that were used to treat HIV was driven up 50 times by the Martin Shkreli, a previous drug firm executive has been condemned seven-year imprisonment by a New York government court for cheating investors.

The “Pharma Bro” was indicted a year ago to defraud investors by demonstrating counterfeit record explanations of two failing hedge funds that he ran.

As per the PBS reports, the 34-year-old pharmaceutical official, who had gained notoriety for driving up the cost of HIV medicine in 2015 and trolling commentators on the web, cried in the court and apologized to investors and said “I am terribly sorry I lost your trust,” he reportedly said in the court. “You deserve far better.

In spite of the fact that his lawyers requested for tolerance in condemning, the U.S. District Judge Kiyo Matsumoto termed his crimes seriously and handed him the sentence.

Related Posts

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

Senores Pharma to Buy Two Teva ANDAs

Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Senores Pharma to Buy Two Teva ANDAs

Senores Pharma to Buy Two Teva ANDAs

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lilly launches Mounjaro KwikPen in India

Lilly launches Mounjaro KwikPen in India